Cargando…
Carnosine Did Not Affect Vascular and Metabolic Outcomes in Patients with Prediabetes and Type 2 Diabetes: A 14-Week Randomized Controlled Trial
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with prediabetes and type 2 diabetes mellitus (T2DM). Carnosine has been suggested as a potential approach to reduce ASCVD risk factors. However, there is a paucity of human data. Hence, we per...
Autores principales: | Saadati, Saeede, Cameron, James, Menon, Kirthi, Hodge, Alexander, Lu, Zhong X., de Courten, Maximilian, Feehan, Jack, de Courten, Barbora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674211/ https://www.ncbi.nlm.nih.gov/pubmed/38004228 http://dx.doi.org/10.3390/nu15224835 |
Ejemplares similares
-
Nutritional Interventions for COVID-19: A Role for Carnosine?
por: Feehan, Jack, et al.
Publicado: (2021) -
Use of carnosine in the prevention of cardiometabolic risk factors in overweight and obese individuals: study protocol for a randomised, double-blind placebo-controlled trial
por: Menon, Kirthi, et al.
Publicado: (2021) -
Does supplementation with carnosine improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-blind, placebo-controlled trial
por: Baye, Estifanos, et al.
Publicado: (2017) -
Effects of supplementation with carnosine and other histidine-containing dipeptides on chronic disease risk factors and outcomes: protocol for a systematic review of randomised controlled trials
por: Menon, Kirthi, et al.
Publicado: (2018) -
The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
por: Menon, Kirthi, et al.
Publicado: (2022)